Compare SWX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWX | RYTM |
|---|---|---|
| Founded | 1931 | 2008 |
| Country | United States | United States |
| Employees | 2453 | 414 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.2B |
| IPO Year | 2017 | 2017 |
| Metric | SWX | RYTM |
|---|---|---|
| Price | $88.90 | $88.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $87.40 | ★ $131.14 |
| AVG Volume (30 Days) | 416.9K | ★ 713.2K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ 120.29 | 28.34 |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $5,433,972,000.00 | N/A |
| Revenue This Year | $18.48 | $55.34 |
| Revenue Next Year | $2.61 | $86.06 |
| P/E Ratio | $45.88 | ★ N/A |
| Revenue Growth | ★ 9.56 | N/A |
| 52 Week Low | $67.65 | $58.71 |
| 52 Week High | $94.43 | $122.20 |
| Indicator | SWX | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 47.71 |
| Support Level | $87.84 | $87.19 |
| Resistance Level | $93.93 | $92.17 |
| Average True Range (ATR) | 1.91 | 4.91 |
| MACD | -0.50 | 0.15 |
| Stochastic Oscillator | 20.27 | 41.94 |
Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.